DOI: 10.4244/EIJV7I1A28

Valve thrombosis after transcatheter heart valve implantation

Edgar L.W. Tay*, MBBS, MRCP; Ronen Gurvitch, MD; Namal Wijeysinghe, MD; Fabian Nietlispach, MD; David Wood, MD; Mike Allard, MD; Brad Munt, MD; Anson Cheung, MD; John G.Webb, MD, FACC

Case 1

A 66-year-old male with prior coronary artery bypass (CABG) and chronic lung disease presented with class III dyspnoea. Echocardiography (TTE) confirmed severe aortic stenosis with a left ventricular ejection fraction (EF) of 30%. He was deemed unsuitable for conventional surgery. Warfarin (for low EF) was discontinued five days prior while 600 mg of clopidogrel and 325 mg of aspirin were loaded three hours before transcatheter valve implantation (TVI). Heparin (5000 IU) was administered during the procedure. Asize 23 mm Edwards SAPIEN™ (Edwards Lifesciences Inc., Irvine, CA) valve was implanted. Post implant echocardiography showed thrombi on the valve (Figure 1 A) hence heparin was continued. Three days later, the patient had acardiovascular arrest. Telemetry revealed sinus arrest with a slow ventricular escape. Cardiopulmonary resuscitation was unsuccessful. An autopsy showed that the valve was well seated with good cusp mobility and no pericardial effusion. Thrombi were however seen on the stent frame (Figure 1 B)

Figure 1. Panel A: Transesophageal echocardiogram of patient 1. Left ventricular outflow tract seen in the long axis demonstrating the stent (long white arrow), thrombus on the stent (short white arrow) and the thickened valve leaflets (white arrow heads). LA: left atrium; Ao: aorta; LV: left ventricle. Panel B. Post-mortem image of thrombi on the outflow stent frame of the transcatheter valve (black arrow) of patient 1. Panel C. 2D transesophageal echocardiography of patient 2. This long axis view shows a thrombus (asterix) situated between the first surgical mitral valve (white arrow) and the stent of the THV (yellow arrow). The transcatheter valve leaflets are also thickened (white arrowheads) Panel D. 3D transesophageal echocardiography showing the thrombus from the atrial side in patient 2. The original surgical mitral sewing ring (white arrow) and the transcatheter valve (black arrow) are seen.

Case 2

A 77-year-old lady with a history of CABG and mitral valve replacement for rheumatic mitral stenosis (MS) presented with pulmonary oedema. TTE confirmed severe bioprosthetic mitral regurgitation (MR) and moderate MS (mean gradient of 10mmHg). ATVI was offered due to frailty. Aspirin 81mg was continued while clopidogrel 600 mg was loaded two hours prior to the procedure. Asize 26 mm Edwards SAPIEN valve was deployed transapically. MR was abolished and transmitral gradient fell to 7mmHg. She was discharged on clopidogrel 75 mg and aspirin 81mg daily. Echocardiography for evaluation of dyspnoea a month later showed athrombus attached to the edge of the Edwards SAPIEN valve (Figures 1C and 1D). Anticoagulation was instituted and she was discharged uneventfully.

These cases show that thrombi can develop early after TVI despite dual antiplatelet therapy (DAPT). The experience gathered from surgical bioprosthetic valves show that thromboembolic risks are highest in the first three months following valve implantation1. It is however unclear if this is mirrored in TVI. Whether the current recommendation of DAPT for six months (PARTNER protocol and recommendation for Medtronic Corevalve2 is adequate for all patients remains to be clearly tested.

Conflict of interest statement

Drs. Webb and Cheung are consultants to Edwards Lifesciences. The other authors have no conflict of interest to declare.

Volume 7 Number 1
May 17, 2011
Volume 7 Number 1
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV10I2A44 Jun 20, 2014
Two cases of thrombotic stenosis in SAPIEN XT valves after transapical implantation
Leetmaa T et al
free

IMAGE IN CARDIOLOGY

10.4244/EIJV10I11A233 Mar 20, 2015
Pseudo early degeneration of a transcatheter aortic valve prosthesis due to thrombosis
de Brito Jr F et al
free

10.4244/EIJV11SWA28 Sep 17, 2015
Antithrombotic therapy in TAVI patients: changing concepts
Gargiulo G et al
free

10.4244/EIJV15I7A102 Sep 20, 2019
Antithrombotic therapy after TAVI: where are we going?
Wilkins B et al
free

10.4244/EIJV9SSA9 Sep 15, 2013
Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?
Collet J and Montalescot G
free

10.4244/EIJV9I9A189 Jan 20, 2014
What embolises to the brain during transcatheter aortic valve implantation?
Van Mieghem NM et al
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA7 Sep 18, 2016
Leaflet motion abnormality after TAVI: genuine threat or much ado about nothing?
Chakravarty T et al
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved